Results 101 to 110 of about 400,118 (290)
Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or ...
Brian V. Balgobind +19 more
doaj +1 more source
Single‐cell RNA/TCR/BCR sequencing reveals that 5CAR therapy in T‐ALL induces T‐cell exhaustion, reduces EBV‐associated TCRs, lowers TCR/BCR diversity, and increases NK/DC/monocyte activation and function. In contrast, 7CAR therapy reduces multiple pathogen‐associated TCRs, enhances NK cell activation and function, decreases monocyte activation, and ...
Yuechen Luo +12 more
wiley +1 more source
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
Eliane Nguyen +8 more
doaj +1 more source
DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss
Senescent bone marrow stromal cells accumulate in the aging bone microenvironment, promoting bone degeneration. DEL‐1, an endogenous secreted protein, acts as a natural senolytic that selectively eliminates these cells. By engaging a β3 integrin/CD73/adenosine/p38 MAPK/BCL‐2 pathway, DEL‐1 counters aging‐related bone loss, revealing promising ...
Jong‐Hyung Lim +11 more
wiley +1 more source
Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core +1 more source
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
Background Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia.
Ion Cristóbal +6 more
doaj +1 more source
Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang +9 more
wiley +1 more source
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of
Edurne San José-Enériz +29 more
doaj +1 more source
Background Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib.
Fabrizio Vianello +10 more
doaj +1 more source

